Corporate Information

• 20 Apr, 2022
  Spago Nanomedical presents its Q1 report and provides company update
• 20 Apr, 2022
  Spago Nanomedical presenterar delårsrapport och ger bolagsuppdatering
• 19 Apr, 2022
  Extended SpagoPix patent protection in Japan
• 19 Apr, 2022
  Förlängt patentskydd för SpagoPix i Japan
• 11 Apr, 2022
  Notice to Annual General Meeting of Spago Nanomedical AB (publ)
• 11 Apr, 2022
  Kallelse till årsstämma i Spago Nanomedical AB (publ)
• 22 Mar, 2022
  Spago Nanomedical presents its platform technology at ACS Spring today
• 25 Feb, 2022
  Spago Nanomedical receives go-ahead to include patients with pancreatic cancer in the clinical study SPAGOPIX-01
• 25 Feb, 2022
  Spago Nanomedical får klartecken att inkludera patienter med pankreascancer i den kliniska studien SPAGOPIX-01
• 25 Jan, 2022
  Significantly reduced tumor growth with Tumorad® according to new preclinical results